Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01864343
Other study ID # STATIM-Pilot
Secondary ID MUW_492/2011
Status Completed
Phase N/A
First received May 17, 2013
Last updated May 24, 2013
Start date September 2011
Est. completion date May 2013

Study information

Verified date May 2013
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority Austria: Agency for Health and Food Safety
Study type Interventional

Clinical Trial Summary

The primary goal in the treatment of acute myocardial infarction is to reperfuse the ischemic myocardium to reduce infarct size. Animal data and human data suggest that whole-body cooling to temperatures below 35°C before revascularisation can additionally reduce infarct size and therefore improves outcome in these patients.

The purpose of the study is to determine the feasibility and safety of a combined cooling strategy started in the out-of-hospital arena for achieving pre-reperfusion hypothermia in patients with acute st-elevation myocardial infarction.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date May 2013
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Age between 18 and 75 years

- Immediately transfer to cath-lab is possible

- Anterior or inferior ST-Elevation myocardial infarction

- ST-Segment elevation of >0.2mV in 2 or more anatomically contiguous leads

- Duration of symptoms <6 hours

Exclusion Criteria:

- Participation in another study

- Patients presenting with cardiac arrest

- Tympanic temperature of <35.0°C prior enrolment

- Thrombolysis therapy

- Previous myocardial infarction in medical history

- Previous percutaneous coronary intervention or coronary artery bypass graft

- Severe heart failure (defined as a New York Heart Association (NYHA) score of III or IV), Killip class II through IV at presentation

- Clinical signs of infection

- End-stage kidney disease or hepatic failure

- Recent stroke (within the last six month)

- Conditions that may be exacerbated by hypothermia, such as haematological dyscrasias, oral anticoagulant treatment with international normalized radio >1.5, severe pulmonary disease

- Pregnancy. Women of childbearing potential are excluded

- Allergy to meperidine, buspirone, magnesium, or polyvinyl chloride

- Use of a monoamine oxidase inhibitor such as selegiline in the previous 14 days

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
EMCOOLS flex pad; Philips Innercool RTx
Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)

Locations

Country Name City State
Austria Medical University of Vienna Vienna

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of a combined cooling strategy for achieving a core temperature of <35.0°C at the time of reperfusion of the infarct related artery Blood temperature will be recorded at the time of first wire-crossed lesion of the infarct related coronary stenosis Time of reperfusion of the culprit lesion in st-elevation myocardial infarction (expected average 120 minutes) No
Secondary Safety of a combined cooling strategy as an adjunctive therapy on primary percutaneous coronary intervention in acute st-elevation myocardial infarction Incidence of major adverse cardiac events as defined as: death, heart failure, pulmonary edema, recurrent MI, malignant arrhythmias (i.e. ventricular fibrillation, sustained ventricular tachycardia) emergent stent revascularisation, any hospitalisation, major/minor bleeding (according to TIMI-bleeding score), infection (clinical relevant infection with the need of systemic antimicrobiotic therapy) within a period of 45±15 days within 45 days (+/- 15 days) Yes
Secondary Tolerability of a combined cooling strategy as an adjunctive therapy on primary percutaneous coronary intervention in acute st-elevation myocardial infarction Patients are monitored for incidence of shivering using a 4-point scale: 0, no shivering evident; 1, isolated facial or masticatory fasciculation; 2, peripheral shivering; 3, uncontrolled rigor during the cooling procedure (in average the first 4 hours) during active cooling and rewarming (in average the first 4 hours) No
Secondary Time to revascularisation (first medical contact to balloon time) The time to reperfusion of the infarct related artery is crucial in acute ST-elevation myocardial infarction. To evaluate if the cooling procedure has a substantial influence on this time frame we measure the time from first medical contact to reperfusion. Time of reperfusion (in average 120 minutes) No
See also
  Status Clinical Trial Phase
Completed NCT00962416 - Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI) Phase 4
Active, not recruiting NCT00927615 - Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO) N/A
Completed NCT03135275 - MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial N/A
Recruiting NCT02592694 - Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty Phase 4
Withdrawn NCT01991366 - Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
Completed NCT02158468 - Effect of Conditioning on Myocardial Damage in STEMI N/A
Completed NCT01197729 - OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry N/A
Completed NCT06426537 - Colchicine's Efficacy in MI Patients: Comparing PCI and Non-Reperfusion Approaches Early Phase 1
Completed NCT01882179 - Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size Phase 3
Terminated NCT00719914 - A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks Phase 2
Completed NCT00952224 - Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance - Impact on Outcome N/A
Completed NCT00378391 - European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry N/A
Withdrawn NCT04303377 - Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction Phase 2
Completed NCT03523624 - Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
Completed NCT01531114 - PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus Phase 3
Active, not recruiting NCT01960933 - Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization N/A
Completed NCT00502528 - Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction Phase 2
Recruiting NCT02062554 - Brasilia Heart Study
Recruiting NCT04150016 - In-stent Repair and Vessel Reaction of STEMI Patients With OCT N/A
Recruiting NCT03074214 - Prognostic Value of Copeptin for Infarct Size and Prognosis in Patients With ST-elevation Myocardial Infarction N/A